Cargando…

MammaPrint and BluePrint comprehensively capture the cancer hallmarks in early‐stage breast cancer patients

MammaPrint® (MP) is a 70‐gene signature that stratifies early‐stage breast cancer patients into low‐ and high risk of distant relapse. Further stratification of MP risk results identifies four risk subgroups, ultra‐low (UL), low, high 1, and high 2, with specific prognostic and predictive outcomes....

Descripción completa

Detalles Bibliográficos
Autores principales: Haan, Josien C., Bhaskaran, Rajith, Ellappalayam, Architha, Bijl, Yannick, Griffioen, Christian J., Lujinovic, Ersan, Audeh, William M., Penault‐Llorca, Frédérique, Mittempergher, Lorenza, Glas, Annuska M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9299843/
https://www.ncbi.nlm.nih.gov/pubmed/34841595
http://dx.doi.org/10.1002/gcc.23014
_version_ 1784751070625398784
author Haan, Josien C.
Bhaskaran, Rajith
Ellappalayam, Architha
Bijl, Yannick
Griffioen, Christian J.
Lujinovic, Ersan
Audeh, William M.
Penault‐Llorca, Frédérique
Mittempergher, Lorenza
Glas, Annuska M.
author_facet Haan, Josien C.
Bhaskaran, Rajith
Ellappalayam, Architha
Bijl, Yannick
Griffioen, Christian J.
Lujinovic, Ersan
Audeh, William M.
Penault‐Llorca, Frédérique
Mittempergher, Lorenza
Glas, Annuska M.
author_sort Haan, Josien C.
collection PubMed
description MammaPrint® (MP) is a 70‐gene signature that stratifies early‐stage breast cancer patients into low‐ and high risk of distant relapse. Further stratification of MP risk results identifies four risk subgroups, ultra‐low (UL), low, high 1, and high 2, with specific prognostic and predictive outcomes. BluePrint® (BP) is an 80‐gene signature that classifies breast tumors as basal, luminal, or HER2 molecular subtype. To gain insight into their biological significance, we annotated the MP 70‐ and BP 80‐genes with respect to the 10 hallmarks of cancer (HoC). Furthermore, we related gene expression profiles of the extreme ends of the MP low‐ and high‐risk patients (here called, ultra‐low (UL) and ultra‐high (UH) or High2, respectively), to the 10 HoC per BP subtype by differential gene expression and pathway analysis. MP and BP gene functions reflected all 10 HoCs. Most MP and BP genes were associated with sustaining proliferative signaling, followed by genome instability and mutation categories. Based on the gene expression profiles, UL and UH subgroup pathways were down ‐or upregulated, respectively, reflecting proliferative and metastatic features, such as G2M checkpoint, DNA repair, oxidative phosphorylation, immune invasion, PI3K/AKT/mTOR signaling, and hypoxia pathways. Notably, the UH HER2‐type was enriched in several immune signaling pathways, such as IL2/STAT5 signaling and TNFα signaling via NFκB. Our results show that MP and BP gene signatures represent and capture all 10 HoCs and highlight underlying biological processes of MP extreme samples, which might guide treatment decisions as the signature captures the full spectrum of early breast cancers.
format Online
Article
Text
id pubmed-9299843
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley & Sons, Inc.
record_format MEDLINE/PubMed
spelling pubmed-92998432022-07-21 MammaPrint and BluePrint comprehensively capture the cancer hallmarks in early‐stage breast cancer patients Haan, Josien C. Bhaskaran, Rajith Ellappalayam, Architha Bijl, Yannick Griffioen, Christian J. Lujinovic, Ersan Audeh, William M. Penault‐Llorca, Frédérique Mittempergher, Lorenza Glas, Annuska M. Genes Chromosomes Cancer Research Articles MammaPrint® (MP) is a 70‐gene signature that stratifies early‐stage breast cancer patients into low‐ and high risk of distant relapse. Further stratification of MP risk results identifies four risk subgroups, ultra‐low (UL), low, high 1, and high 2, with specific prognostic and predictive outcomes. BluePrint® (BP) is an 80‐gene signature that classifies breast tumors as basal, luminal, or HER2 molecular subtype. To gain insight into their biological significance, we annotated the MP 70‐ and BP 80‐genes with respect to the 10 hallmarks of cancer (HoC). Furthermore, we related gene expression profiles of the extreme ends of the MP low‐ and high‐risk patients (here called, ultra‐low (UL) and ultra‐high (UH) or High2, respectively), to the 10 HoC per BP subtype by differential gene expression and pathway analysis. MP and BP gene functions reflected all 10 HoCs. Most MP and BP genes were associated with sustaining proliferative signaling, followed by genome instability and mutation categories. Based on the gene expression profiles, UL and UH subgroup pathways were down ‐or upregulated, respectively, reflecting proliferative and metastatic features, such as G2M checkpoint, DNA repair, oxidative phosphorylation, immune invasion, PI3K/AKT/mTOR signaling, and hypoxia pathways. Notably, the UH HER2‐type was enriched in several immune signaling pathways, such as IL2/STAT5 signaling and TNFα signaling via NFκB. Our results show that MP and BP gene signatures represent and capture all 10 HoCs and highlight underlying biological processes of MP extreme samples, which might guide treatment decisions as the signature captures the full spectrum of early breast cancers. John Wiley & Sons, Inc. 2021-12-11 2022-03 /pmc/articles/PMC9299843/ /pubmed/34841595 http://dx.doi.org/10.1002/gcc.23014 Text en © 2021 The Authors. Genes, Chromosomes and Cancer published by Wiley Periodicals LLC. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Research Articles
Haan, Josien C.
Bhaskaran, Rajith
Ellappalayam, Architha
Bijl, Yannick
Griffioen, Christian J.
Lujinovic, Ersan
Audeh, William M.
Penault‐Llorca, Frédérique
Mittempergher, Lorenza
Glas, Annuska M.
MammaPrint and BluePrint comprehensively capture the cancer hallmarks in early‐stage breast cancer patients
title MammaPrint and BluePrint comprehensively capture the cancer hallmarks in early‐stage breast cancer patients
title_full MammaPrint and BluePrint comprehensively capture the cancer hallmarks in early‐stage breast cancer patients
title_fullStr MammaPrint and BluePrint comprehensively capture the cancer hallmarks in early‐stage breast cancer patients
title_full_unstemmed MammaPrint and BluePrint comprehensively capture the cancer hallmarks in early‐stage breast cancer patients
title_short MammaPrint and BluePrint comprehensively capture the cancer hallmarks in early‐stage breast cancer patients
title_sort mammaprint and blueprint comprehensively capture the cancer hallmarks in early‐stage breast cancer patients
topic Research Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9299843/
https://www.ncbi.nlm.nih.gov/pubmed/34841595
http://dx.doi.org/10.1002/gcc.23014
work_keys_str_mv AT haanjosienc mammaprintandblueprintcomprehensivelycapturethecancerhallmarksinearlystagebreastcancerpatients
AT bhaskaranrajith mammaprintandblueprintcomprehensivelycapturethecancerhallmarksinearlystagebreastcancerpatients
AT ellappalayamarchitha mammaprintandblueprintcomprehensivelycapturethecancerhallmarksinearlystagebreastcancerpatients
AT bijlyannick mammaprintandblueprintcomprehensivelycapturethecancerhallmarksinearlystagebreastcancerpatients
AT griffioenchristianj mammaprintandblueprintcomprehensivelycapturethecancerhallmarksinearlystagebreastcancerpatients
AT lujinovicersan mammaprintandblueprintcomprehensivelycapturethecancerhallmarksinearlystagebreastcancerpatients
AT audehwilliamm mammaprintandblueprintcomprehensivelycapturethecancerhallmarksinearlystagebreastcancerpatients
AT penaultllorcafrederique mammaprintandblueprintcomprehensivelycapturethecancerhallmarksinearlystagebreastcancerpatients
AT mittempergherlorenza mammaprintandblueprintcomprehensivelycapturethecancerhallmarksinearlystagebreastcancerpatients
AT glasannuskam mammaprintandblueprintcomprehensivelycapturethecancerhallmarksinearlystagebreastcancerpatients